VeraVue Single-Use Flexible Cystoscope Gets Limited Market Release

Boston Scientific recently announced the limited market release of VeraVue Single-Use Flexible Cystoscope, which received FDA 510(k) clearance in October 2023. Developed and manufactured by Medimaging Integrated Solutions and marketed and exclusively sold by Boston Sci through a distribution agreement, the scope is intended to help clinicians diagnose and treat urinary tract conditions, providing visualization of the lining of the bladder and urethra while displaying images to perform various diagnostic procedures.

Unlike reusable scopes, VersaVue helps optimize schedule and workflow by eliminating the time associated with reprocessing, repair, and maintenance, according to the company, and may help reduce patient wait times associated with a lack of available reusable options. Additionally, the cystoscope come in sterilized packaging for every patient, removing the risk of infection caused by possible cross-contamination of reusable scopes.

The system is designed to be lightweight and compact for easy transportation across clinical settings and includes the 14” VersaVue Tablet to display images and video.

“The VersaVue Single-Use Flexible Cystoscope was developed as an alternative to reusable flexible cystoscopes,” Ron Morton, MD, chief medical officer, Urology, at Boston Scientific, told MD+DI. “By utilizing a unique sterile packaged cystoscope for each patient, practices can eliminate the risk of infection due to cross-contamination associated with reusable scopes. Moreover, opposed to relying on the availability of reprocessed scopes being able to open a new scope for each case may also help improve the outpatient clinic experience by eliminating wait times and or cancellations due to lack of reusable scope availability.”

Currently, the cystoscope is only commercially available in the US.